Rathmell: We must put the individual at the center of our approach to ending cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Dear Colleagues,

When I started this column, I was wanting to retain the sense of connection that I had to the greater cancer community as I stepped away into a period of disconnection.

This era is built on the foundations of decades of diligent work to deeply understand the various mechanisms that drive cancer. And it will evolve further as we arrive at even deeper understandings.

I am immensely grateful to the editorial staff for giving me this outlet, and I have been elevated by the avenue it presented to hear from more voices as guest editors. Our community is even richer and more connected than I ever realized. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
W. Kimryn Rathmell, MD, PhD, MMHC
Former director, National Cancer Institute
Table of Contents

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
Confidential Trump administration budget documents show that the upcoming FY26 Budget Request will radically cut about $50 billion out of the U.S. Department of Health and Human Services, reshuffling agency components, and slashing the number of NIH institutes and centers to just eight. 
W. Kimryn Rathmell, MD, PhD, MMHC
Former director, National Cancer Institute

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login